Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF

Siragusa, S., Passamonti, F., Cervantes, F., Tefferi, A. (2009). Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients. AMERICAN JOURNAL OF HEMATOLOGY, 84(3), 140-143 [10.1002/ajh.21651].

Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients.

SIRAGUSA, Sergio;
2009-01-01

Abstract

Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF
2009
Settore MED/15 - Malattie Del Sangue
Siragusa, S., Passamonti, F., Cervantes, F., Tefferi, A. (2009). Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients. AMERICAN JOURNAL OF HEMATOLOGY, 84(3), 140-143 [10.1002/ajh.21651].
File in questo prodotto:
File Dimensione Formato  
Am J Hematol 2009.pdf

Solo gestori archvio

Dimensione 121.33 kB
Formato Adobe PDF
121.33 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/47401
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact